Latest news with #GCG
GMA Network
29-05-2025
- Business
- GMA Network
Maharlika Fund chief Consing submits courtesy resignation
The top honcho of the country's first and only sovereign wealth fund, the Maharlika Investment Corporation (MIC), on Thursday confirmed he has tendered his courtesy resignation, as the Marcos administration's ongoing executive overhaul was also extended to heads of state-run firms. 'We at the Maharlika Investment Corporation (MIC) fully support President Ferdinand R. Marcos Jr.'s directive for courtesy resignations among GOCC (government-owned and -controlled corporations) leaders. We view this as an important and standard measure to uphold accountability and further strengthen public service,' MIC president and CEO Rafael Consing said in a statement. 'In line with this, I have submitted my unqualified courtesy resignation,' Consing said. This came after the Governance Commission for GOCCs (GCG) directed state-run firms' non ex-officio chairpersons, chief executive officers (CEOs), and all appointive directors/trustees/members of their respective GOCCs' governing boards to immediately submit their courtesy resignations to the President through the Office of the Executive Secretary. 'The entire MIC Board of Directors also promptly complied, submitting their courtesy resignations immediately upon receiving the relevant memorandum from the Governance Commission for GOCCs (GCG),' Consing said. 'We will all continue to diligently perform our respective duties and responsibilities until advised otherwise,' he added. The state-run firm's Board of Directors include GOCC-representatives Land Bank of the Philippines president Lynette Ortiz and Development Bank of the Philippines president Michael de Jesus as directors; regular director Vicky Castillo Tan; and independent directors Andrew Jerome Gan, German Lichauco II, and Roman Felipe Reyes. While top executives of GOCCs were ordered to resign, the GCG said that until any action is taken by the Office of the President on their courtesy resignations, 'they shall continue to report for work and perform their usual duties and functions…' The MIC was created through Republic Act No. 11954 or the Maharlika Investment Fund (MIF) Act of 2023, signed by Marcos in July 2023, with the aim to tap state assets for investment ventures to generate additional public funds. The MIC manages the MIF—a pool of funds initially sourced from state-run financial institutions that will be invested in foreign currencies, fixed-income instruments, domestic and foreign corporate bonds, joint ventures, mergers and acquisitions, real estate, and high-impact infrastructure projects. Under the law, the MIC has an authorized capital stock of P500 billion, P375 billion of which shall have corresponding common shares available for subscription by the national government, its agencies or instrumentalities, government-owned and controlled corporations or GFIs, and government financial institutions. Its initial capitalization is sourced from the national government and the country's two largest state-run banks. The Landbank transferred P50 billion and the DBP P25 billion to the Maharlika Fund. The national government will contribute P50 billion from the following sources: Bangko Sentral ng Pilipinas' total declared dividends; National government's share from the income of PAGCOR Properties, real and personal identified by the DOF-Privatization and Management Office; Other sources such as royalties and/or special assessments In January, MIC made its first investment activity by acquiring a 20% stake in Synergy Grid and Development Philippines Inc. (SGP) —giving it two board seats in the company and another two in the National Grid Corporation of the Philippines (NGCP). The NGCP is 60% owned by SGP, while State Grid Corporation of China has 40%. MIC had expressed intent in acquiring shares of the State Grid Corporation of China in the Philippines' power grid. Last week, Marcos directed the courtesy resignations of Cabinet secretaries to "recalibrate" his administration after the 2025 national and local elections. The President had lamented that results of the May 2025 midterm polls showed that the people are "tired of politics and they are disappointed with the government." —AOL, GMA Integrated News
Time of India
28-05-2025
- Politics
- Time of India
Students remove pillars to stop ‘encroachment' of Government College for Girls ground in Ludhiana.
Ludhiana: Students of Government College for Girls (GCG) on Wednesday protested against the installation of pillars and fence in the college ground. They raised slogans against authorities for allowing such 'encroachment' of making a fence in the college ground. Controversy erupted as part of the GCG ground being fenced to turn it in into a parking space for Durga Mata Mandir across the road. But the students protested the move and said that the land belonged to the college where they hold their sports activities. "We need this space for sports and other activities. We practice here and this space cannot be taken away. The college would expand, such encroachment and giving away of the college land should not be done," Jasman Kaur, a student of the college said. "The college land belongs to the students and it should not given to anyone under any condition," Anita, another protesting student said. It is pertinent to mention that Rajya Sabha MP Sanjeev Arora had written to Punjab education minister Harjot Singh Bains that the land of Government College for Girls should be allotted for parking for Durga Mata Mandir. But after the activity for earmarking land started taking place in the sports ground, students got to know about it and started protesting against the move. Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 5 Books Warren Buffett Wants You to Read In 2025 Blinkist: Warren Buffett's Reading List Undo They also held protest at DC office on Monday in this regard, but still fencing of the land started. "This is highly ironic that the the government college land is being allocated for parking. Even though this government has been making big claims about improving education, here prime land of a reputed educational institute is being grabbed. We have been asking under which rule or authority was such step was being done in the college, but nobody is answering. The land belongs to the students," said Ranvir Singh, president, Punjab Students' Union. "The MP or the ministry or the administration should come forward and debate with us why this land is being allocated for parking purpose. Alternatives for parking space for temple should be explored, but land of the college cannot be given at any cost. The is the space for the colleges and students. Action must be taken against the contractors and all involved who started encroaching the college ground," Amandeep Singh Kheowali, national coordinator for Punjab Students' Union. Educationists have also condemned the move. Brij Bhushan Goyal from SCD Government College Alumni Association said, "The Government College for Girls should be given grant for research and institute and made a deemed university. But instead, even the existing land of the college is being encroached upon," he said. "An educational institute that has given so much to Punjab, so many students from the college are serving as educationists. This too is a temple of education, and land is being encroached upon to make space for temple parking is highly condemnable. No educated person would tolerate such encroachment," he said. Former principals express shock Manjit Kaur Sodhia, former principal, Government College for Girls, said, "I have been really perturbed ever since I got to know about this. Even if I have to lay my life, I will do it, but I will not let even an inch of the land of my college to be encroached upon. There have been such attempts earlier as well. When I was a principal, we had stopped such attempts," she said. "This land is only and only for education and for students. When I was the principal, then MP Lala Lajpat Rai about 35 years ago and the govt tried to get this ground land allocated and many other attempts were made, but I put my foot down. No individual has rights to interfere in the college and try to encroach upon or grab the land of the college," she said. Another former principal Dr Mohinder Kaur Grewal said, "We had never allowed such a situation to escalate. Though the ground is for a short duration like 5-7 days is given on lease for exhibitions etc, but never for a regular parking space.. I have been a student here, then taught and became the principal here. There were such attempts earlier when we used to be told and got letters from authorities, but we never let it happen. We used to get orders, and even used to get letters, we have been resiting and fighting. Anything and everything is happening for vote bank politics these days," she said. "It is the primary responsibility of the staff to safeguard the institution," she said. "Students, teachers and principal must take a stand and don't let the land be given at any cost whatsoever," she added.
Yahoo
26-05-2025
- Health
- Yahoo
Phase 3 Clinical Study of Mazdutide in Chinese Adults with Overweight or Obesity (GLORY-1) Published in The New England Journal of Medicine (NEJM)
SAN FRANCISCO and SUZHOU, China, May 26, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, announces that the results of a Phase 3 clinical study of mazdutide , a dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist, in Chinese adults with overweight or obesity (GLORY-1) have been published in The New England Journal of Medicine (NEJM) with a related editorial [ The first authors of this paper are Professor Linong Ji from Peking University People's Hospital and Professor Jiang Hongwei from the First Affiliated Hospital of Henan University of Science and Technology. In addition, Professor Linong Ji and Dr. Lei Qian from Innovent Biologics, served as the co-corresponding authors. This marks the first time that a clinical study of mazdutide, the world's first dual GCG/GLP-1 receptor agonist submitted for marketing, has been featured in a top-tier, peer-reviewed medical journal. It is also the first time a clinical trial of an innovative metabolic and endocrine therapy developed in China has been published in NEJM, a milestone that highlights China's growing capabilities in drug development and biotechnology innovation. This publication is expected to contribute to the evolving global clinical guidelines for the treatment of overweight and obesity. Regarding this groundbreaking new study, Professors Vanita R. Aroda of Harvard Medical School and Brigham and Women's Hospital, Boston, and Leigh Perreault of the University of Colorado Anschutz Medical Campus jointly commented that the GLORY-1 trial reveals distinct characteristics in the Chinese population compared to Western populations. Specifically, younger individuals in China exhibit metabolic dysfunction at rates comparable to or even exceeding those in older Western populations. The dual GCG/GLP-1 receptor agonist therapy demonstrated not only significant reductions in body weight and BMI but also comprehensive improvements in obesity-associated systemic health risks. Moreover, they emphasized that obesity interventions in China must adopt differentiated strategies tailored to local population features, with a focus on liver health and lipid management. Given the earlier onset of obesity in China and its heavier societal burden, earlier intervention is critical—and yields greater long-term benefits. For emerging obesity therapies, the experts noted that pharmacological treatments are only one component of a broader strategy. They advocated for synergizing drug therapies with public health policies to build a comprehensive prevention and treatment system, addressing the global obesity epidemic more effectively. Mazdutide is expected to launch in China this year, with anticipated approvals for weight management and glycemic control. Recognized for its superior weight loss efficacy and comprehensive metabolic benefits, mazdutide has been ranked among FIERCE Pharma's 2025 Top 10 Most Anticipated Drugs. In the GLORY-1 study, a total of 610 participants with obesity (BMI ≥ 28 kg/m2) or overweight (24 kg/m2 ≤ BMI < 28 kg/m2) with at least one obesity-related comorbidity were enrolled and randomized to receive mazdutide 4 mg, 6 mg, or placebo, administered subcutaneously once weekly for 48 weeks. The co-primary endpoints were the percentage change in body weight from baseline and a weight reduction of ≥5% at week 32. At baseline, the mean weight was 87.2 kg, and the mean BMI was 31.1 kg/m 2. The study results showed that mazdutide significantly reduced body weight compared to placebo at both 4 mg and 6 mg doses. Based on the efficacy estimand, the mean percent change from baseline in body weight was −10.97%, −13.38%, and −0.24% at Week 32 and −12.05%, −14.84%, and −0.47% at Week 48 in the mazdutide 4 mg, 6 mg, and placebo groups, respectively. A total of 76.3% of participants in the mazdutide 4 mg group and 84.0% in the mazdutide 6 mg group had a weight reduction of ≥5% at week 32, compared with 10.9% in the placebo group; 37.0% of participants in the mazdutide 4 mg group and 50.6% in the mazdutide 6 mg group had a weight reduction of ≥15% at week 48, compared with 2.1% in the placebo group. The primary endpoint and all key secondary endpoints of the study showed statistically significant superiority to placebo with p-values < 0.001 (main results as follows).Efficacy Estimand1 Treatment-policy estimand2Mazdutide 4 mg (N=203) Mazdutide 6 mg (N=202) Placebo (N = 205) Mazdutide 4 mg (N=203) Mazdutide 6 mg (N=202) Placebo (N = 205) Co-primary endpoints (Week 32) Percent weight reduction −10.97% −13.38% −0.24% −10.09% −12.55% 0.45 % Achieved a weight reduction ≥5% 76.3 % 84.0 % 10.9 % 73.9 % 82.0 % 10.5 % Some key secondary endpoints (Week 48) Percent weight reduction −12.05% −14.84% −0.47% −11.00% −14.01% 0.30 % Achieved a weight reduction ≥5% 73.5 % 82.8 % 11.5 % 71.6 % 81.6 % 10.8 % Achieved a weight reduction ≥10% 55.2 % 67.9 % 2.9 % 53.5 % 66.7 % 2.6 % Achieved a weight reduction ≥15% 37.0 % 50.6 % 2.1 % 35.7 % 49.5 % 2.0 % Waist circumference reduction −9.48 cm −10.96 cm −1.48 cm −9.12 cm −10.72 cm −1.41 cm 1. Efficacy estimand aims to estimate the study treatment effect when participants adhered to the planned treatment regimen. 2. Treatment policy estimand aims to evaluate the efficacy regardless of intercurrent events (early discontinuation of study treatment and initiation of new anti-obesity medication or bariatric surgery). Mazdutide also significantly reduced blood pressure, blood lipids (total cholesterol, triglycerides, and low-density lipoprotein cholesterol), serum uric acid, transaminase levels, and other cardiovascular and metabolic indicators. In addition, mazdutide significantly reduced liver fat content. Among participants with baseline liver fat content ≥ 5%, the mean percent changes in liver fat content from baseline to week 48 were −63.26%, −73.18%, and +8.20% in the mazdutide 4 mg, 6 mg, and placebo groups, respectively; Among participants with baseline liver fat content ≥ 10%, the mean percent change from baseline in liver fat content to week 48 were −65.85%, −80.24%, and −5.27% in the mazdutide 4 mg, 6 mg, and placebo groups, respectively. Good overall safety and tolerability of mazdutide were reported. The overall safety profile of the mazdutide group was consistent with findings from previous studies of mazdutide and aligned with that of other GLP-1 receptor agonists. The most frequently reported treatment-emergent adverse events included nausea, diarrhea, and vomiting, which were mostly mild or moderate in severity. At Week 48, both the mean change from baseline in heart rate was 2.6 beats per minute in both the mazdutide 4 mg and 6 mg groups. There were no safety signals of increased cardiovascular risk observed throughout the study. Professor Linong Ji, the Leading Principal Investigator of the Study, Peking University People's Hospital, stated, "For decades, global obesity management guidelines have predominantly relied on data from Caucasian populations, resulting in limited applicability to Asian demographics. Meanwhile, China's overweight/obese population exhibits distinct clinical characteristics and therapeutic needs compared to Western populations, necessitating evidence-based weight management strategies specifically tailored for Chinese patients. For most Chinese patients with overweight or obesity, the recommended weight loss target should be 5%-15% reduction maintained over 3-6 months. Moderate-to-severe obesity patients may require more ambitious goals. The GLORY-1 study, conducted in Chinese populations aligned with these targets, demonstrated promising outcomes: mazdutide achieved >15% weight reduction in nearly half of participants, indicating its efficacy across people living with overweight to severe obesity. Published in The New England Journal of Medicine, the GLORY-1 study not only signifies international recognition of China's innovative research in endocrine-metabolic disorders but also underscores the pioneering innovation of Chinese biopharmaceutical industry. Mazdutide's successful development will accelerate domestic enterprises' strategic presence in obesity management, enabling comprehensive, personalized solutions for China's overweight/obese population throughout their treatment journey." Dr. Lei Qian from Innovent Biologics, stated, "Mazdutide is globally first dual GCG/GLP-1 receptor agonist to be approved soon. The publication of its pivotal study GLORY-1 in The New England Journal of Medicine marks a breakthrough in China's drug development in endocrine and metabolic diseases. The study provides robust, high-quality clinical evidence for treating overweight and obesity in Chinese adults and will undoubtedly influence future clinical guidelines, diagnostic criteria, and standards of care. This academic achievement also demonstrates the exceptional clinical research capabilities of Chinese investigators and the solid innovative R&D abilities of Innovent. With mazdutide's imminent approval in China, we look forward to offering an advanced therapeutic option to improve the health and quality of life of individuals living with overweight or obesity. As an innovative pharmaceutical company, Innovent has actively responded to and promoted the goal of 'Healthy China 2030' by advancing science-based weight management through strategic collaborations and cutting-edge medical achievements. " About Obesity China has the world's largest population of individuals with overweight or obesity[1], a trend that is likely to rise. Obesity is associated to multiple comorbidities, and is a major contributor to reduced life expectancy and quality of life. In 2019, overweight and obesity accounted for 11.1% of deaths from chronic non-communicable diseases in China, nearly doubling from 5.7% in 1990[2]. Despite the chronic nature of obesity and its need for long-term management, treatment options remain limited. While lifestyle interventions remains the cornerstone of treatment, many patients struggle to achieve or maintain meaningful weight reduction. This underscores the urgent need for safe, effective and sustainable pharmacological interventions. About Mazdutide (IBI362) Innovent entered into an exclusive license agreement with Eli Lilly and Company (Lilly) for the development and potential commercialization of OXM3 (also known as mazdutide), a GLP-1R and GCGR dual agonist, in China. As a mammalian oxyntomodulin (OXM) analogue, mazdutide may offer additional benefits beyond those of GLP-1 receptor agonists—such as promoting insulin secretion, lowering blood glucose and reducing body weight—by also activating the glucagon receptor to increase energy expenditure and improve hepatic fat metabolism. Mazdutide has demonstrated excellent weight loss and glucose-lowering effects in clinical studies. It has also shown benefits in reducing waist circumference, blood lipids, blood pressure, blood uric acid, liver enzymes, and liver fat content, as well as improving insulin sensitivity. Mazdutide currently has two NDAs accepted for review by NMPA, including: For chronic weight management in adults with overweight or obesity; For glycemia control in adults with type 2 diabetes. Mazdutide is currently being evaluated in six Phase 3 clinical studies, including: GLORY-1: A Phase 3 trial in Chinese participants with overweight or obesity. GLORY-2: A Phase 3 trial in Chinese participants with moderate-to-severe obesity. GLORY-3: A Phase 3 trial comparing mazdutide and semaglutide in Chinese participants with overweight/obesity and metabolic dysfunction-associated fatty liver disease (MAFLD). DREAMS-1: A Phase 3 trial in treatment-naïve Chinese patients with T2D. DREAMS-2: A Phase 3 trial comparing mazdutide and dulaglutide in Chinese T2D patients with inadequate glycemic control on oral antidiabetic drugs. DREAMS-3: A Phase 3 trial comparing mazdutide and semaglutide in Chinese patients with T2D and obesity. Among these, GLORY-1, DREAMS-1 and DREAMS-2 studies have all met their endpoints, and other studies are currently ongoing. In addition, several new clinical studies of mazdutide are planned, including: A Phase 3 trial in adolescents with obesity. A Phase 3 trial in Chinese participants with moderate-to-severe obstructive sleep apnea (OSA) and obesity. New studies in metabolic dysfunction-associated steatohepatitis (MASH) and heart failure with preserved ejection fraction (HFpEF). About Innovent Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 15 products in the market. It has 3 new drug applications under regulatory review, 4 assets in Phase III or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center. Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit or follow Innovent on Facebook and LinkedIn. Statement: (1) Innovent does not recommend the use of any unapproved drug (s)/indication (s). (2) Ramucirumab (Cyramza) and Selpercatinib (Retsevmo) and Pirtobrutinib (Jaypirca) were developed by Eli Lilly and Company. Forward-looking statement This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent's competitive environment and political, economic, legal and social conditions. Innovent, the Directors and the employees of Innovent assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect. References [1] Pan XF, Wang L, Pan A. Epidemiology and determinants of obesity in China. Lancet Diabetes Endocrinol 2021; 9: 373–92. [2] Institute for Health Metrics and Evaluation. Global Health Data Exchange. GBD results tool. (accessed Jan 10, 2021). View original content: SOURCE Innovent Biologics
Yahoo
26-05-2025
- Health
- Yahoo
Phase 3 Clinical Study of Mazdutide in Chinese Adults with Overweight or Obesity (GLORY-1) Published in The New England Journal of Medicine (NEJM)
SAN FRANCISCO and SUZHOU, China, May 26, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, announces that the results of a Phase 3 clinical study of mazdutide , a dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist, in Chinese adults with overweight or obesity (GLORY-1) have been published in The New England Journal of Medicine (NEJM) with a related editorial [ The first authors of this paper are Professor Linong Ji from Peking University People's Hospital and Professor Jiang Hongwei from the First Affiliated Hospital of Henan University of Science and Technology. In addition, Professor Linong Ji and Dr. Lei Qian from Innovent Biologics, served as the co-corresponding authors. This marks the first time that a clinical study of mazdutide, the world's first dual GCG/GLP-1 receptor agonist submitted for marketing, has been featured in a top-tier, peer-reviewed medical journal. It is also the first time a clinical trial of an innovative metabolic and endocrine therapy developed in China has been published in NEJM, a milestone that highlights China's growing capabilities in drug development and biotechnology innovation. This publication is expected to contribute to the evolving global clinical guidelines for the treatment of overweight and obesity. Regarding this groundbreaking new study, Professors Vanita R. Aroda of Harvard Medical School and Brigham and Women's Hospital, Boston, and Leigh Perreault of the University of Colorado Anschutz Medical Campus jointly commented that the GLORY-1 trial reveals distinct characteristics in the Chinese population compared to Western populations. Specifically, younger individuals in China exhibit metabolic dysfunction at rates comparable to or even exceeding those in older Western populations. The dual GCG/GLP-1 receptor agonist therapy demonstrated not only significant reductions in body weight and BMI but also comprehensive improvements in obesity-associated systemic health risks. Moreover, they emphasized that obesity interventions in China must adopt differentiated strategies tailored to local population features, with a focus on liver health and lipid management. Given the earlier onset of obesity in China and its heavier societal burden, earlier intervention is critical—and yields greater long-term benefits. For emerging obesity therapies, the experts noted that pharmacological treatments are only one component of a broader strategy. They advocated for synergizing drug therapies with public health policies to build a comprehensive prevention and treatment system, addressing the global obesity epidemic more effectively. Mazdutide is expected to launch in China this year, with anticipated approvals for weight management and glycemic control. Recognized for its superior weight loss efficacy and comprehensive metabolic benefits, mazdutide has been ranked among FIERCE Pharma's 2025 Top 10 Most Anticipated Drugs. In the GLORY-1 study, a total of 610 participants with obesity (BMI ≥ 28 kg/m2) or overweight (24 kg/m2 ≤ BMI < 28 kg/m2) with at least one obesity-related comorbidity were enrolled and randomized to receive mazdutide 4 mg, 6 mg, or placebo, administered subcutaneously once weekly for 48 weeks. The co-primary endpoints were the percentage change in body weight from baseline and a weight reduction of ≥5% at week 32. At baseline, the mean weight was 87.2 kg, and the mean BMI was 31.1 kg/m 2. The study results showed that mazdutide significantly reduced body weight compared to placebo at both 4 mg and 6 mg doses. Based on the efficacy estimand, the mean percent change from baseline in body weight was −10.97%, −13.38%, and −0.24% at Week 32 and −12.05%, −14.84%, and −0.47% at Week 48 in the mazdutide 4 mg, 6 mg, and placebo groups, respectively. A total of 76.3% of participants in the mazdutide 4 mg group and 84.0% in the mazdutide 6 mg group had a weight reduction of ≥5% at week 32, compared with 10.9% in the placebo group; 37.0% of participants in the mazdutide 4 mg group and 50.6% in the mazdutide 6 mg group had a weight reduction of ≥15% at week 48, compared with 2.1% in the placebo group. The primary endpoint and all key secondary endpoints of the study showed statistically significant superiority to placebo with p-values < 0.001 (main results as follows).Efficacy Estimand1 Treatment-policy estimand2Mazdutide 4 mg (N=203) Mazdutide 6 mg (N=202) Placebo (N = 205) Mazdutide 4 mg (N=203) Mazdutide 6 mg (N=202) Placebo (N = 205) Co-primary endpoints (Week 32) Percent weight reduction −10.97% −13.38% −0.24% −10.09% −12.55% 0.45 % Achieved a weight reduction ≥5% 76.3 % 84.0 % 10.9 % 73.9 % 82.0 % 10.5 % Some key secondary endpoints (Week 48) Percent weight reduction −12.05% −14.84% −0.47% −11.00% −14.01% 0.30 % Achieved a weight reduction ≥5% 73.5 % 82.8 % 11.5 % 71.6 % 81.6 % 10.8 % Achieved a weight reduction ≥10% 55.2 % 67.9 % 2.9 % 53.5 % 66.7 % 2.6 % Achieved a weight reduction ≥15% 37.0 % 50.6 % 2.1 % 35.7 % 49.5 % 2.0 % Waist circumference reduction −9.48 cm −10.96 cm −1.48 cm −9.12 cm −10.72 cm −1.41 cm 1. Efficacy estimand aims to estimate the study treatment effect when participants adhered to the planned treatment regimen. 2. Treatment policy estimand aims to evaluate the efficacy regardless of intercurrent events (early discontinuation of study treatment and initiation of new anti-obesity medication or bariatric surgery). Mazdutide also significantly reduced blood pressure, blood lipids (total cholesterol, triglycerides, and low-density lipoprotein cholesterol), serum uric acid, transaminase levels, and other cardiovascular and metabolic indicators. In addition, mazdutide significantly reduced liver fat content. Among participants with baseline liver fat content ≥ 5%, the mean percent changes in liver fat content from baseline to week 48 were −63.26%, −73.18%, and +8.20% in the mazdutide 4 mg, 6 mg, and placebo groups, respectively; Among participants with baseline liver fat content ≥ 10%, the mean percent change from baseline in liver fat content to week 48 were −65.85%, −80.24%, and −5.27% in the mazdutide 4 mg, 6 mg, and placebo groups, respectively. Good overall safety and tolerability of mazdutide were reported. The overall safety profile of the mazdutide group was consistent with findings from previous studies of mazdutide and aligned with that of other GLP-1 receptor agonists. The most frequently reported treatment-emergent adverse events included nausea, diarrhea, and vomiting, which were mostly mild or moderate in severity. At Week 48, both the mean change from baseline in heart rate was 2.6 beats per minute in both the mazdutide 4 mg and 6 mg groups. There were no safety signals of increased cardiovascular risk observed throughout the study. Professor Linong Ji, the Leading Principal Investigator of the Study, Peking University People's Hospital, stated, "For decades, global obesity management guidelines have predominantly relied on data from Caucasian populations, resulting in limited applicability to Asian demographics. Meanwhile, China's overweight/obese population exhibits distinct clinical characteristics and therapeutic needs compared to Western populations, necessitating evidence-based weight management strategies specifically tailored for Chinese patients. For most Chinese patients with overweight or obesity, the recommended weight loss target should be 5%-15% reduction maintained over 3-6 months. Moderate-to-severe obesity patients may require more ambitious goals. The GLORY-1 study, conducted in Chinese populations aligned with these targets, demonstrated promising outcomes: mazdutide achieved >15% weight reduction in nearly half of participants, indicating its efficacy across people living with overweight to severe obesity. Published in The New England Journal of Medicine, the GLORY-1 study not only signifies international recognition of China's innovative research in endocrine-metabolic disorders but also underscores the pioneering innovation of Chinese biopharmaceutical industry. Mazdutide's successful development will accelerate domestic enterprises' strategic presence in obesity management, enabling comprehensive, personalized solutions for China's overweight/obese population throughout their treatment journey." Dr. Lei Qian from Innovent Biologics, stated, "Mazdutide is globally first dual GCG/GLP-1 receptor agonist to be approved soon. The publication of its pivotal study GLORY-1 in The New England Journal of Medicine marks a breakthrough in China's drug development in endocrine and metabolic diseases. The study provides robust, high-quality clinical evidence for treating overweight and obesity in Chinese adults and will undoubtedly influence future clinical guidelines, diagnostic criteria, and standards of care. This academic achievement also demonstrates the exceptional clinical research capabilities of Chinese investigators and the solid innovative R&D abilities of Innovent. With mazdutide's imminent approval in China, we look forward to offering an advanced therapeutic option to improve the health and quality of life of individuals living with overweight or obesity. As an innovative pharmaceutical company, Innovent has actively responded to and promoted the goal of 'Healthy China 2030' by advancing science-based weight management through strategic collaborations and cutting-edge medical achievements. " About Obesity China has the world's largest population of individuals with overweight or obesity[1], a trend that is likely to rise. Obesity is associated to multiple comorbidities, and is a major contributor to reduced life expectancy and quality of life. In 2019, overweight and obesity accounted for 11.1% of deaths from chronic non-communicable diseases in China, nearly doubling from 5.7% in 1990[2]. Despite the chronic nature of obesity and its need for long-term management, treatment options remain limited. While lifestyle interventions remains the cornerstone of treatment, many patients struggle to achieve or maintain meaningful weight reduction. This underscores the urgent need for safe, effective and sustainable pharmacological interventions. About Mazdutide (IBI362) Innovent entered into an exclusive license agreement with Eli Lilly and Company (Lilly) for the development and potential commercialization of OXM3 (also known as mazdutide), a GLP-1R and GCGR dual agonist, in China. As a mammalian oxyntomodulin (OXM) analogue, mazdutide may offer additional benefits beyond those of GLP-1 receptor agonists—such as promoting insulin secretion, lowering blood glucose and reducing body weight—by also activating the glucagon receptor to increase energy expenditure and improve hepatic fat metabolism. Mazdutide has demonstrated excellent weight loss and glucose-lowering effects in clinical studies. It has also shown benefits in reducing waist circumference, blood lipids, blood pressure, blood uric acid, liver enzymes, and liver fat content, as well as improving insulin sensitivity. Mazdutide currently has two NDAs accepted for review by NMPA, including: For chronic weight management in adults with overweight or obesity; For glycemia control in adults with type 2 diabetes. Mazdutide is currently being evaluated in six Phase 3 clinical studies, including: GLORY-1: A Phase 3 trial in Chinese participants with overweight or obesity. GLORY-2: A Phase 3 trial in Chinese participants with moderate-to-severe obesity. GLORY-3: A Phase 3 trial comparing mazdutide and semaglutide in Chinese participants with overweight/obesity and metabolic dysfunction-associated fatty liver disease (MAFLD). DREAMS-1: A Phase 3 trial in treatment-naïve Chinese patients with T2D. DREAMS-2: A Phase 3 trial comparing mazdutide and dulaglutide in Chinese T2D patients with inadequate glycemic control on oral antidiabetic drugs. DREAMS-3: A Phase 3 trial comparing mazdutide and semaglutide in Chinese patients with T2D and obesity. Among these, GLORY-1, DREAMS-1 and DREAMS-2 studies have all met their endpoints, and other studies are currently ongoing. In addition, several new clinical studies of mazdutide are planned, including: A Phase 3 trial in adolescents with obesity. A Phase 3 trial in Chinese participants with moderate-to-severe obstructive sleep apnea (OSA) and obesity. New studies in metabolic dysfunction-associated steatohepatitis (MASH) and heart failure with preserved ejection fraction (HFpEF). About Innovent Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 15 products in the market. It has 3 new drug applications under regulatory review, 4 assets in Phase III or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center. Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit or follow Innovent on Facebook and LinkedIn. Statement: (1) Innovent does not recommend the use of any unapproved drug (s)/indication (s). (2) Ramucirumab (Cyramza) and Selpercatinib (Retsevmo) and Pirtobrutinib (Jaypirca) were developed by Eli Lilly and Company. Forward-looking statement This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent's competitive environment and political, economic, legal and social conditions. Innovent, the Directors and the employees of Innovent assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect. References [1] Pan XF, Wang L, Pan A. Epidemiology and determinants of obesity in China. Lancet Diabetes Endocrinol 2021; 9: 373–92. [2] Institute for Health Metrics and Evaluation. Global Health Data Exchange. GBD results tool. (accessed Jan 10, 2021). View original content: SOURCE Innovent Biologics Sign in to access your portfolio
Mid East Info
22-04-2025
- Business
- Mid East Info
GCG Enterprise Solutions Launches 'G-Sign' Version 2 - Middle East Business News and Information
UAE Government Approved Digital Signature Solution Evolves to Deliver Feature-Packed Upgrade Dubai, United Arab Emirates: GCG (Gulf Commercial Group) Enterprise Solutions, a leading provider of Digital Transformation, Print, IT and AV Solutions has announced that its proprietary 'G-Sign' digital signature solution will shortly be receiving a feature-packed update. G-Sign V2 is being primed for market release within Q2-2025 and follows-up on the successful debut of this proprietary solution back in June 2023. As the first-of-it-kind digital signature solutions approved by the UAE Government, G-Sign uniquely extends easy integration with UAE Pass, making it the preferred choice of regional enterprises and government entities. The upgraded V2 of G-Sign now deliver a powerhouse of new features aimed at empowering enterprises with greater safety, speed and agility: Enhanced UI/UX : Improved visual appeal plus seamless, engaging user experience via simplified navigation, enhanced design consistency and optimized accessibility. : Improved visual appeal plus seamless, engaging user experience via simplified navigation, enhanced design consistency and optimized accessibility. New Mobile App : Integrates with newly developed mobile app. Advanced features enable users to access and interact with the system effortlessly, at anytime from anywhere. : Integrates with newly developed mobile app. Advanced features enable users to access and interact with the system effortlessly, at anytime from anywhere. Smarter Configuration Management : Over 60 customizable settings are now available through an intuitive interface for effortless system setup. : Over 60 customizable settings are now available through an intuitive interface for effortless system setup. Flexible Role Management : Comes with built-in Super Admin, Department Admin, and User Roles for enhanced control and customizable permissions. : Comes with built-in Super Admin, Department Admin, and User Roles for enhanced control and customizable permissions. Dynamic Licensing Model : Flexible and adaptable licensing approach that adjusts based on factors like usage, number of users, number of documents, or scale. : Flexible and adaptable licensing approach that adjusts based on factors like usage, number of users, number of documents, or scale. Customizable Email Templates : Enabling tailored participant communications with fully configurable email templates and enhanced content keys. : Enabling tailored participant communications with fully configurable email templates and enhanced content keys. Improved Document Rendering : For enhanced document (such as PDFs, Word files, or images) display and processing in the system. : For enhanced document (such as PDFs, Word files, or images) display and processing in the system. Integration Capability with HSM: Ability to connect and work seamlessly with a Hardware Security Module (HSM). Commenting on the development, Waleed Alawadi, Head of Digital Transformation at GCG Enterprise Solutions stated that: 'At GCG Enterprise Solutions, we have consistently remained at the forefront of technological innovation, which are empowering enterprises to lead into the future. G-Sign Version 2 builds on our original success with robust enhancements that deliver significant benefits in terms of increased security, efficiency, cost savings, and compliance – all of which are essential tools for modern enterprises and governments'. G-Sign V2, much like its predecessor will continue to be offered through an annual subscription model, with the GCG Enterprise Solutions team extending their full support.
